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Estrogen plus progestin hormone therapy (HT) is associated with an increased risk of postmenopausal breast
cancer, but few studies have examined the impact of HT use on the risk of breast cancer in younger women. We
assessed the association between estrogen plus progestin HT or unopposed estrogen HT and young-onset breast
cancer using data from the Two Sister Study (2008–2010), a sister-matched study of 1,419 cases diagnosed with
breast cancer before the age of 50 years and 1,665 controls. We assessed exposures up to a family-specific index
age to ensure comparable opportunities for exposures and used propensity scores to control for birth cohort effects
on HT use. Ever HT use was uncommon (7% and 11% in cases and controls, respectively). Use of estrogen plus
progestin was not associated with an increased risk of young-onset breast cancer (odds ratio = 0.80, 95% confi-
dence interval: 0.41, 1.59). Unopposed estrogen use was inversely associated with the risk of young-onset breast
cancer (odds ratio = 0.58, 95% confidence interval: 0.34, 0.99). Duration of use, age at first use, and recency of use
did not modify these associations.
hormone therapy; propensity score; young-onset breast cancer
Abbreviations: CI, confidence interval; E-HT, unopposed estrogen hormone therapy; EP-HT, combined estrogen and progestin
hormone therapy; HT, hormone therapy; P-HT, progestin alone hormone therapy; WHI, Women’s Health Initiative.
Breast cancer is the leading contributor to cancer incidence
in women in the United States, with an estimated 232,340
new invasive and 64,640 new in situ breast cancer cases in
2013 (1). Although incidence increases with age, approxi-
mately 25% of diagnoses occur before the age of 50 years (2).
There are some etiologic and clinical differences between
young-onset and older-onset breast cancer. For example, obe-
sity is associated with reduced risk before but not after meno-
pause (3–5), and later age at menarche might be a stronger risk
factor for premenopausal breast cancer than for postmenopau-
sal breast cancer (6–8). Younger cases tend to present with a
higher histological grade and more advanced stage than later-
onset cases and aremore likely to have triple-negative or human
epidermal growth factor receptor-2–positive cancer (9, 10).
Hormone therapy (HT) comprises estrogen and/or proges-
tin/progesterone usually taken in the form of pills or patches.
Women take HT for a range of indications, including but not
limited to relief of menopausal symptoms, replacement of
hormone levels after oophorectomy, migraine prevention,
or osteoporosis prevention. Although most users are peri-
or postmenopausal, there is some use among young or pre-
menopausal women.
In many observational studies and randomized controlled
trials, it has been reported that postmenopausal women treated
with combined estrogen and progestin HT (EP-HT) experi-
ence an increased risk of breast cancer (11–21). In particular,
in the Women’s Health Initiative (WHI) (21), investigators
found that postmenopausal women randomized to EP-HT
had a hazard ratio of 1.26 (95% confidence interval (CI):
1.00, 1.59) for breast cancer relative to placebo users. Longer
durations of EP-HT may further increase risk, although these
associations seem to dissipate once treatment ends (11–13,
15, 18–21).
The effects of unopposed estrogen therapy (E-HT), which
is contraindicated in women with intact uteri because of the
risk of endometrial cancer (22), are less clear (11, 12, 15–20).
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In a second WHI trial restricted to women who were 50–79
years of age with no uterus, those randomized to E-HT were
less likely to develop breast cancer than were controls who
took placebos (hazard ratio = 0.77, 95% CI: 0.62, 0.95) (23).
Few studies have examined progestin alone (P-HT), but some
have suggested an increased risk (11, 15, 18, 24).
The association between HT and breast cancer in young
women has been examined in several studies (7, 25–31),
but only 2 studies (29, 30) differentiated between types of
HT. Shantakumar et al. (30) found odds ratios of 3.51 (95%
CI: 1.45, 8.49) and 1.17 (95% CI: 0.23, 5.88) for the associ-
ations of premenopausal breast cancer with use of EP-HT and
E-HT, respectively. Palmer et al. (29) found weak evidence
that women under 50 years of age who took E-HT for at least
5 years had increased risk of breast cancer (relative risk = 1.6,
95% CI: 0.3, 8.5). We used data from the Two Sister Study, a
sister-matched case-control study, to examine whether use of




The Two Sister Study is a sister-matched case-control study
of young-onset breast cancer. Control sisters were recruited












No. % No. % No. %
Index age, years
<40 3,657 24 334 20 296 21
40–44 5,396 35 602 36 496 35
≥45 6,474 42 729 44 627 44
Raceb
Non-Hispanic white 12,646 81 1,485 89 1,252 88
Black 1,515 10 73 4 70 5
Hispanic 940 6 63 4 57 4
Other 422 3 43 3 40 3
Relative birth order among included sisters
First (oldest) 915 55 527 37
Second 606 36 792 56
Third or younger 144 9 100 7
Educational levelc
Less than a college degree 4,854 31 436 30 387 27
Associate, technical, or bachelor’s degree 7,084 46 776 46 678 48
Master’s or doctoral degree 3,584 23 393 24 354 25
Age at menarche, yearsd
<12 2,943 19 276 17 268 19
12–13 8,742 56 953 57 833 59
≥14 3,830 25 435 26 318 22
Paritye
0 births 3,636 23 357 21 303 21
1 births 2,598 17 259 16 226 16
2 births 5,791 37 617 37 553 39
≥3 births 3,502 23 431 26 337 24
Age at which first term (≥37 weeks) pregnancy ended, yearsf
<25 4,678 41 470 37 328 31
25–29 3,766 33 459 36 396 37
30–34 2,164 19 235 19 255 24
≥35 837 7 102 8 87 8
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from the Sister Study, a prospective cohort study of 50,884
women without breast cancer who had a full or half sister
who had been diagnosed with breast cancer. Sister Study par-
ticipants who were 35–74 years of age and lived in the United
States or Puerto Rico were enrolled between 2003 and 2009.
Between 2008 and 2010, we invited affected full sisters
(cases) to participate in the Two Sister Study if they had been
diagnosed with breast cancer within the past 4 years and be-
fore 50 years of age. We enrolled 1,422 cases and 1,689 con-
trols. We excluded control sisters whowere more than 7 years
younger than their case sisters if an older control sister had
also been interviewed (n = 19). We also excluded 5 women
whowere originally enrolled as controls but went on to be di-
agnosed with breast cancer at a younger age than their case
sister. Three cases with no remaining eligible control sisters
then had to be excluded. This left 1,419 eligible cases and
1,665 eligible controls in the Two Sister Study sample.
All participants provided written or verbal consent and com-
pleted computer-assisted telephone interviews, which included
questions about reproductive history, health conditions, and
lifestyle factors (32–36). To ensure similar accrual times for
medical and exposure histories, all sisters in a family were as-
signed the same index age, which was the minimum of the age












No. % No. % No. %
Average body mass index from ages 30 to 39 yearsg
<25.0 10,959 71 1,206 72 1,032 73
25.0–29.9 2,951 19 311 19 283 20
≥30.0 1,536 10 144 9 98 7
Use of hormonal birth controlh
None 1,712 11 160 10 129 9
Used 1–6 years before index age 4,070 26 472 28 427 30
Used >6 years before index age 9,660 62 1,026 62 854 61
Menopausal status at index agei
Premenopausal 12,852 83 1,391 84 1,239 87
Postmenopausal, age at menopause <41 years 754 5 74 4 28 2
Postmenopausal, age at menopause ≥41 years 723 5 67 4 56 4
Hysterectomy with retained ovarian tissue 1,179 8 131 8 96 7
Had menopausal symptoms at index agej 4,077 27 448 27 256 18
Surgical status at index agek
None 13,397 86 1,439 86 1,282 88
Hysterectomy only 1,188 8 132 8 96 7
Oophorectomy only 21 0 2 0 1 0
Hysterectomy and oophorectomy 907 6 91 5 39 3
Visited dentist in past 12 monthsl 13,182 85 1,454 87 1,218 86
Recall time >5 yearsm 6,726 43 535 32 255 18
a Limited to women with a sister who was diagnosed before 50 years age and who had a recall time of less than
10 years. The mean age for included participants in the Sister Study was 47.1 years (range, 35.1–59.8 years).
b Data were missing for 4 Sister Study participants and 1 control.
c Data were missing for 5 Sister Study participants.
d Data were missing for 12 Sister Study participants and 1 control.
e Data were missing for 1 control.
f Data were missing for 4,082 Sister Study participants, 399 Two Sister Study controls, and 353 Two Sister Study
cases.
g Data were missing for 81 Sister Study participants, 4 Two Sister Study controls, and Two Sister Study 6 cases.
Body mass index was measured as weight (kg)/height (m)2.
h Data were missing for 39 Sister Study participants, 6 Two Sister Study controls, and 8 Two Sister Study cases.
i Data were missing for 19 Sister Study participants and 2 controls.
j Data were missing for 243 Sister Study participants, 7 Two Sister Study controls, and 4 Two Sister Study cases.
k Data were missing for 14 Sister Study participants, 1 Two Sister Study control, and 1 Two Sister Study case.
l Data were missing for 3 Sister Study participants.
m Recall time was defined as the difference in years between interview age and index age.
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completion of the baseline interview. The institutional review
board of the National Institute of Environmental Health Sci-
ences approved both studies, as did the Copernicus Group.
Cases included both invasive and in situ cancers. At base-
line, participants reported whether they had ever used any
form of HT. HT users were further questioned about type of
therapy and ages at which they started and stopped. Using this
information, we reconstructed each participant’s exposure
history. Women who reported using HT via patches, pills, in-
jections, or other oral administrations (e.g., lozenges or tablets)
were considered users. Pill or patch use was most common
(91%). Women who exclusively used creams, suppositories,
or gels were considered nonusers (n = 5).
Women who had used EP-HT were classified as EP-HT
users even if they had used E-HT (n = 14) or P-HT (n = 3)
at another time. Those who had used E-HT and P-HT at dif-
ferent times were classified as E-HT users (n = 5). If the index
agewas equal to the case’s age at diagnosis, we reset the index
age to 1 year younger for all sisters in the family. This was done
to allow for latencies in effects.
HT users were further subdivided according to duration of
use (<2 years vs.≥2 years), age at first use (<40 years vs.≥40
years), and timing of first use relative to menopause. We also
considered recency of use, including use in the year before
the index age (0–4 vs. ≥5 years prior). Cutpoints were se-
lected to ensure roughly equal numbers for each category.
There were too few P-HT users to permit further stratification.
Women who had had both ovaries removed or who had not
had a menstrual period in the preceding 12 months were con-
sidered to be postmenopausal. Women who were still men-
struating, currently pregnant, or currently breastfeeding were
considered premenopausal, as werewomenwho had been preg-
nant within 1 year of their reported last menstrual period (n = 6).
Women who were premenopausal but who had undergone










No. % No. % OR 95% CI OR 95% CI OR 95% CI
Hormone therapy usedd
None 1,466 88 1,316 93 1.00 Referent 1.00 Referent 1.00 Referent
Unopposed estrogen 115 7 50 4 0.42 0.29, 0.62 0.56 0.33, 0.93 0.58 0.34, 0.99
Estrogen plus progestin 56 3 25 2 0.41 0.24, 0.70 0.61 0.32, 1.15 0.80 0.41, 1.59
Progestin alone 23 1 20 1 1.24 0.66, 2.35 1.42 0.73, 2.78 1.51 0.76, 3.00
Duration of used,e
Never 1,466 90 1,316 95 1.00 Referent 1.00 Referent 1.00 Referent
Unopposed estrogen
≤2 years 57 3 25 2 0.45 0.26, 0.77 0.59 0.32, 1.09 0.59 0.32, 1.08
>2 years 58 4 25 2 0.39 0.22, 0.68 0.39 0.15, 1.04 0.53 0.19, 1.49
Estrogen plus progestin
≤2 years 26 2 14 1 0.59 0.29, 1.24 0.90 0.40, 2.03 1.30 0.55, 3.10
>2 years 30 2 11 1 0.27 0.12, 0.62 0.38 0.14, 1.01 0.48 0.17, 1.37
Age at first used,e
Never 1,466 90 1,316 95 1.00 Referent 1.00 Referent 1.00 Referent
Unopposed estrogen
<40 years 66 4 22 2 0.33 0.19, 0.56 0.49 0.25, 1.00 0.50 0.25, 1.02
≥40 years 49 3 28 2 0.54 0.31, 0.94 0.61 0.30, 1.23 0.63 0.31, 1.28
Estrogen plus progestin
<40 years 21 1 10 1 0.40 0.17, 0.98 0.53 0.19, 1.51 0.64 0.22, 1.86
≥40 years 35 2 15 1 0.40 0.20, 0.81 0.66 0.30, 1.43
Menopausal status at first used,f
Never 1,466 89 1,316 94 1.00 Referent 1.00 Referent 1.00 Referent
Unopposed estrogen
Premenopausal 64 4 29 2 0.41 0.25, 0.69 0.53 0.30, 0.93 0.52 0.29, 0.95
Postmenopausal 51 3 21 2 0.42 0.23, 0.75 0.47 0.12, 1.82 0.60 0.16, 2.32
Estrogen plus progestin
Premenopausal 40 2 23 2 0.63 0.36, 1.10 0.82 0.43, 1.56 0.97 0.49, 1.91
Postmenopausal 18 1 4 0 N/Ag N/Ag N/Ag N/Ag N/Ag N/Ag
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hysterectomy with retention of ovarian tissue were catego-
rized separately. If HT users were missing data for meno-
pausal status and age at menopause, we assumed that they
took HT before menopause (n = 10).
Propensity scores
Because controls were up to 74 years of age at interview and
cases were at most 54 years of age at interview, more than half
of cases (61%) were younger than their control sister(s). The
mean age was identical for the 2 groups (47.3 years), but con-
trols were between 35 and 67 years of age at interview, where-
as cases were between 31 and 54 years of age. Consequently,
cases and controls could systematically differ in their propen-
sity for exposures if there was a birth cohort effect.
After the release of the initial WHI trial results in 2002, HT
use declined dramatically in the United States. In 1999–2000,
38% of women aged 50–59 years reported current HT use
(35), but by 2003–2004, prevalence of use had fallen to 19%.
By 2009–2010, it dropped below 7%. Because 10% of con-
trol sisters and no case sisters had reached the age of 50 years
before 2002whenHTusewaswidespread, bias was a concern
(21, 35). We used propensity score methods to adjust for dif-
ferential opportunity for HT use.
A propensity score is a probability of an exposure given
individual characteristics (36). If accurately modeled, one can
adjust for many confounders and obtain a less-biased esti-
mate of the effect of an exposure on an outcome by including
the propensity scores in a multivariate regression model.
Månsson et al. (36) demonstrated that in a case-control
setting, the best possible propensity score is one modeled using
data from the source population. We used a subcohort of the
Sister Study as a proxy for the Two Sister Study source pop-
ulation and modeled each participant’s propensity for use of
EP-HT, E-HT, or P-HT. The subcohort included Sister Study
participants who had a sister diagnosed before 50 years of age
andwho had less than a 10-year gap between interview age and
index age, which was again defined as the minimum of the sis-
ter’s diagnosis age and the participant’s age at completion of
the computer-assisted telephone interview. A total of 15,527
Sister Study participants met these criteria, including 1,488
who were also serving as controls in the Two Sister Study.
The propensity score model incorporated potential con-











No. % No. % OR 95% CI OR 95% CI OR 95% CI
Recency of use, relative to index ageh
Never 1,450 89 1,308 92 1.00 Referent 1.00 Referent 1.00 Referent
Unopposed estrogen
0–4 years before 89 5 34 2 0.41 0.26, 0.64 0.56 0.28, 1.10 0.58 0.28, 1.20
≥5 years before 31 2 21 2 0.49 0.25, 0.97 0.59 0.29, 1.23 0.62 0.30, 1.30
Estrogen plus progestin
0–4 years before 45 3 17 1 0.32 0.16, 0.62 0.49 0.23, 1.05 1.12 0.47, 2.66
≥5 years before 21 1 10 1 0.48 0.21, 1.11 0.50 0.20, 1.25 0.52 0.21, 1.33
Abbreviations: CI, confidence interval; OR, odds ratio.
a The odds ratios compare users of a particular agent to thosewho never used hormone therapy; each type of hormone therapy was assessed in
a separate conditional logistic regression model.
b Adjusted for birth order (ordinal), menopausal status (premenopausal, postmenopausal and <41 years of age, or postmenopausal and ≥41
years of age), menopausal symptoms (ever or never), hysterectomy/oophorectomy status (no surgery, oophorectomy with or without hysterectomy,
or hysterectomy only), and recall time (>5 years vs. ≤5 years).
c Hormone therapy status was modeled as a 4-level, polytomous variable in Sister Study participants who had a sister diagnosed with breast
cancer before the age of 50 years and within 10 years of the interview date. The following variables were included in the model: menopausal status
(premenopausal, postmenopausal, age at menopause <41 years, postmenopausal, or age at menopause ≥41 years), restricted cubic spline for
year of menopause (centered at 2002) times menopausal status, restricted cubic spline for age in 2002, hysterectomy/oophorectomy status, race
(white vs. nonwhite), menopausal symptoms (ever or never), recent dental visit (yes or no), recall time (>5 years or ≤5 years between interview age
and index age), parity (yes or no), and age at menarche (<13 years of age versus ≥13 years of age). All time-related variables were assessed as of
the index age or 1 year before the case sister’s diagnosis age, whichever came first. The outcome model estimated the association between
hormone therapy and case status in the Two Sisters sample after adjustment for birth order and propensity score (as a restricted cubic spline).
Estrogen plus progestin models were also adjusted for dental visit and menopausal status. Unopposed estrogen models were also adjusted for
surgical status and race.
d Hormone therapy use in participants in the Two Sister Study was assessed as of the index age or 1 year before the case sister’s age at
diagnosis, whichever came first. Sister Study participants were assessed as of their index age (minimum of their interview date and their
affected sister’s age at diagnosis). Data on hormone therapy use were missing for 5 controls and 8 cases.
e Data were missing for 23 controls and 20 cases.
f Data were missing for 21 controls and 18 cases.
g There were too few subjects to estimate the effect.
h Data were missing for 22 controls and 19 cases.
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as well as well-established risk factors for breast cancer (37).
Web Appendix 1 and Web Tables 1 and 2 (available at http://
aje.oxfordjournals.org/) provide a more detailed discussion
of the variables included in the model and how the propensity
score was applied. We also include descriptions of the ob-
served propensity score distributions (Web Tables 3–6,
Web Figures 1–3).
Briefly, we used unconditional polytomous logistic regres-
sion to model the probabilities of EP-HT, E-HT, or P-HT use
versus never use within the Sister Study subcohort and then
applied the fitted propensity model to participants in the Two
Sister Study and calculated 3 estimated probabilities for each
individual. These probabilities were used to estimate each
participant’s conditional probability for all 3 types of HT
use given her individual characteristics. We used likelihood
ratio tests to assess the fit of the propensity model and to iden-
tify covariates that were insufficiently balanced across treat-
ment groups (Web Table 6) (38).
Statistical analysis
We estimated crude and adjusted odds ratios and 95% con-
fidence intervals for the associations of each type of HT with
breast cancer risk in the Two Sister Study using conditional
logistic regression. Nonusers served as the common reference
group for each analysis. Adjusted models included birth order
(an ordinal variable, with the oldest sister assigned a value of
1), menopausal status (premenopausal, postmenopausal and
<41 years of age, or postmenopausal and ≥41 years of age),
presence of menopausal symptoms (yes or no), hysterectomy/
oophorectomy status (no surgery, oophorectomy with or with-
out hysterectomy, or hysterectomy), and length of recall (>5
years vs. ≤5 years between a woman’s interview age and HT
exposure assessment age). We adjusted for relative birth order
to account for the possibility that older siblings influence their
younger siblings’HTuse and the fact that cases in theTwoSister
Study were usually younger than their control sister(s). We also
generated a third set of conditional odds ratios and 95% con-
fidence intervals that included any insufficiently balanced co-
variates and propensity score as a restricted cubic spline. We
compared users of each HT type to nonusers separately, using
the propensity score specific to the treatment category of interest.
Sensitivity analyses
To further minimize possible bias due to a birth cohort ef-
fect, we conducted additional analyses using a restricted study
sample. The restricted sample included sister pairs born less
than 5 years apart (1,085 controls and 974 cases). The sub-
cohort of Sister Study participants used to derive the propensity
score included only those with the same birth years as those in
the restricted sample (1951–1975; n = 16,201). We also exam-
ined whether oophorectomy status modified the association
between HT and young-onset breast cancer.
RESULTS
Most participants in the Two Sister Study werewhite, well-
educated, premenopausal at the index age, and nonobese and
had good access to health care (Table 1). Controls were more
likely to have had hysterectomies, hysterectomies with bi-
lateral oophorectomies, and menopausal symptoms. The se-
lected Sister Study subcohort used for assessing propensities
was very similar to Two Sister Study controls.
E-HT was the most common type of HT used, followed by
EP-HT, though HT use was low overall. More controls than
cases reported using HT, and the crude odds ratios for breast
cancer were less than 1 for every HT category except P-HT
(Table 2). Multivariate-adjusted odds ratios were closer to
the null but still less than 1.
Although we did not ask women to specify why they used
HT, results from the Two Sister Study and the Sister Study
propensity score model (Web Tables 1 and 2) showed that
participants who experienced early menopause, underwent
bilateral oophorectomy, or had menopausal symptoms or
recent visits to the dentist had a high probability of taking
EP-HT. Having menopausal symptoms was also associated
with E-HT use. Other strong predictors of E-HT use included
hysterectomy, bilateral oophorectomy, and early menopause.
Because women with a longer recall period (>5 years) were
less likely to report taking HT before their index age, we ad-
justed for recall time using the propensity score model.
EP-HT use was not strongly associated with young-onset
breast cancer (odds ratio = 0.80, 95% CI: 0.41, 1.59; Table 2)
in the model adjusted for propensity score. Use for more than
2 years was associated with reduced relative risk, but the num-
bers were small and the confidence intervals werewide. Adjust-
ment for recency of use and age at first use did not measurably
modify the associations. E-HT use was inversely associated
with young-onset breast cancer (propensity score odds ratio =
0.58, 95% CI: 0.34, 0.99; Table 2). Adjustment for duration of
use, age at first use, menopausal status at first use, and recency
of use did not appear to modify the association. P-HT use was
associated with a statistically nonsignificant increased risk of
young-onset breast cancer in the propensity score–adjusted
model (odds ratio = 1.51, 95% CI: 0.76, 3.00).
When we restricted the analysis to sister pairs with an age
difference of less than 5 years (Table 3), the findings were less
precise but qualitatively similar. The odds ratio for EP-HTex-
ceeded 1 but the confidence interval was wide. There was no
evidence of an interaction between HT use and oophorec-
tomy status (P = 0.86 and 0.50 for E-HT and EP-HT, respec-
tively; Web Table 7).
DISCUSSION
Our results suggest that neither EP-HT nor E-HT increase the
risk of young-onset breast cancer and that E-HT might be asso-
ciated with a reduced risk. Although the low rate of P-HT usage
resulted in imprecise estimates, we also found some evidence
that P-HT use increased the risk of young-onset breast cancer.
Our finding that E-HT use is associated with a decreased
risk of young-onset breast cancer is consistent with the WHI
findings for postmenopausal breast cancer (24). Although
Shantakumar et al. (30) and Palmer et al. (29) previously
found evidence that E-HT use increased the risk of young-
onset disease, the estimates from both studies were highly im-
precise (3 and 9 E-HT users, respectively).
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Our results are also consistent with the analysis by Nelson
et al. (28) of 40–49-year-old women, in which they reported
that HT users who did not have a uterus (probable E-HT
users) had a reduced risk of young-onset breast cancer com-
pared with former or never users and that HT users who did
have a uterus (probable EP-HT users) had risk similar to
those of former or never users. However, both Chlebowski
et al. (14) and Shantakumar et al. (30) reported elevated
breast cancer risk with EP-HT use, and we had only limited
power (approximately 43%) to detect a difference between
the estimate of 1.26 reported in the WHI and our estimate
of 0.8 (Web Appendix 2, Web Figure 4). No other studies
have examined the relationship between P-HT and young-
onset breast cancer, but several studies targeting older women
also found evidence of increased risk (11, 15, 18, 22).
Although young women who take HT could be a medically
distinct group, most of our HT users were in their 40s and thus
likely to be perimenopausal. Nonetheless, use of hormones can
serve as a surrogate for a range of treatment indications that are
independently associated with a reduced risk of breast cancer,
such as primary ovarian insufficiency, endogenous estrogen
deficiency, gynecologic surgery, menopausal symptoms, or
premature menopause (25, 39–43). Although we adjusted for
these factors and tested for interaction by oophorectomy status,
some residual confounding by indication may persist.
HT users might also be more likely to utilize the medical
system in general. Althoughwedid not have good information
on mammography use before the index age, we adjusted for
health care utilization using a recent dental visit as an indicator.
Any residual confounding due to surveillance bias would
likely result in elevated estimates of breast cancer risk among
HT users.
Menopausal status is a potential source of confounding
in many existing studies of HT. For women at a given age,
those who are premenopausal or perimenopausal are at greater
risk of breast cancer, but they are less likely to be using HT than
are postmenopausal women (12). In an attempt to minimize
bias due to confounding by menopausal status, investigators
might exclude premenopausal and perimenopausal women,
women who have undergone a hysterectomy, and women who
began HT before menopause (12, 14–16). However, because
many women initiate HT after a hysterectomy or at the onset
of menopausal symptoms, we felt that an investigation of the
risk implications of HT in young women was of public health
importance. By including pre- and postmenopausal women, we
were also able to study associations with the timing of HT ini-
tiation, which may be key to identifying critical susceptibility
periods. An additional strength of the Two Sister Study is the
sister-matched design, which presumably controls for unmea-
sured confounders that are similar across sisters.
Study limitations include our small numbers of exposed
women, possible healthy-participant bias, possible surveillance
bias, and possible recall bias. Exact participation rates for the
Two Sister Study are hard to establish, as some contacted cases
might have elected not to contact us because they realized they
were ineligible. Only a small fraction of participants were ex-
plicitly excluded because of death or poor health, andmore than
half of the identified cases participated. Although we cannot
Table 3. Adjusted Odds Ratios for the Association Between Hormone Therapy and Young-Onset Breast Cancer When Analysis Is Restricted to










No. % No. % OR 95% CI OR 95% CI OR 95% CI
Never 964 89 901 93 1.00 Referent 1.00 Referent 1.00 Referent
Unopposed estrogen 76 7 34 4 0.44 0.27, 0.69 0.61 0.33, 1.12 0.60 0.32, 1.15
Estrogen plus progestin 28 3 21 2 0.65 0.33, 1.25 0.95 0.45, 2.03 1.12 0.49, 2.56
Progestin alone 15 1 13 1 1.16 0.53, 2.52 1.26 0.57, 2.78 1.11 0.50, 2.47
Abbreviations: CI, confidence interval; OR, odds ratio.
a Hormone therapy use in participants in the Two Sister Study was assessed as of the index age or 1 year before the case sister’s age at
diagnosis, whichever came first. Sister Study participants were assessed as of their index age (minimum of their interview date and their
affected sister’s age at diagnosis). Data on hormone therapy use were missing for 2 controls and 5 cases in this restricted analysis.
b The odds ratios compare users of a particular agent to thosewho never used hormone therapy; each type of hormone therapy was assessed in
a separate conditional logistic regression model.
c Adjusted for birth order (ordinal), menopausal status (premenopausal, postmenopausal and <41 years of age, or postmenopausal and
≥41 years of age), menopausal symptoms (ever or never), hysterectomy/oophorectomy status (no surgery, oophorectomy with or without
hysterectomy, or hysterectomy only) and recall time (>5 years vs. ≤5 years).
d Hormone therapy status was modeled as a 4-level, polytomous variable in Sister Study participants who had a sister diagnosed with breast
cancer before the age of 50 years and within 10 years of the interview date. The following variables were included in the model: menopausal status
(premenopausal, postmenopausal, age at menopause <41 years, postmenopausal, or age at menopause ≥41 years), restricted cubic spline for
year of menopause (centered at 2002) times menopausal status, restricted cubic spline for age in 2002, hysterectomy/oophorectomy status, race
(white vs. nonwhite), menopausal symptoms (ever or never), recent dental visit (yes or no), recall time (>5 years or ≤5 years between interview age
and index age), parity (yes or no), and age at menarche (<13 years of age versus ≥13 years of age). All time-related variables were assessed as of
the index age or 1 year before the case sister’s diagnosis age, whichever came first. The outcome model estimated the association between
hormone therapy and case status in the Two Sisters sample after adjustment for birth order and propensity score (as a restricted cubic spline).
Estrogen plus progestin models were also adjusted for dental visit and menopausal status. Unopposed estrogen models were also adjusted for
surgical status and race.
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exclude healthy-participant bias, the magnitude of such bias
would be mitigated by the sister-matched design. As noted ear-
lier, theremight be some surveillance bias due to our inability to
capture mammography usage around the index age. However,
differential surveillance would presumably make HT users
more likely to be diagnosed, with the implication that the use
of HT could be even more protective than we estimated.
Recall bias may be present, because controls were more
likely to have a large gap between their interview age and
index age and thosewith longer recall periods were less likely
to report HT use before their index age. We adjusted for recall
time in both the multivariate and propensity score analyses,
but residual confounding might exist. Nonetheless, because
of their shorter recall times, we would expect cases to report
HT use more often than controls, and therefore recall bias
would not explain the evident protective association of E-
HT use seen here. Our sensitivity analyses that excluded sis-
ter pairs with large age differences also served to reduce recall
bias. The similarity of these results with the main findings sug-
gests that recall bias was not influential.
The fact that control sisters tended to be slightly older than
their case sisters is also a concern. Although this tendency
helped ensure that controls were cancer-free at the age that
their sister was diagnosed, it produced a potentially biasing
birth cohort effect related to the sharply declining use of HT in
the early 2000s. We controlled for this effect by adjusting for
individualized propensity scores. Propensity scores are not typ-
ically applied to case-control studies, but wewere able tomodel
well-informed, stable propensity estimates by using a large sub-
cohort of the Sister Study (36). This subcohort represents the
source population for the Two Sister Study. We further equal-
ized the opportunity for exposure by evaluating all covariates at
an index age that occurred before either sister was diagnosed.
The use of an index age both controlled for age and eliminated
effects due to any behavioral changes brought about by having
a sister diagnosed with breast cancer. We do acknowledge,
however, that this novel application of propensity scores to a
matched case-control study has not been validated.
To our knowledge, this is the largest study to examine the
association between HT use and young-onset breast cancer
and the first conducted in the post-WHI era. This research in-
forms the trade-offs between risks and benefits of HT for
young women, who might take it to help manage symptoms
of early or surgically induced menopause. Our findings sug-
gest that for women under 50 years of age, EP-HT use does
not increase risk but that E-HT, indicated only for women
who have undergone hysterectomy, might be associated with
a reduced risk of young-onset breast cancer.
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